| Dr Gilbert Reid Melson Iii, DO | |
|
2122 Helton Dr, Florence, AL 35630-1449 | |
| (256) 415-8680 | |
| (256) 367-4990 |
| Full Name | Dr Gilbert Reid Melson Iii |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 9 Years |
| Location | 2122 Helton Dr, Florence, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235512591 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of Tennessee Valley Inc | Florence, AL | Hospice |
| North Alabama Medical Center | Florence, AL | Hospital |
| Helen Keller Hospital | Sheffield, AL | Hospital |
| Mitchell-hollingsworth Nursing & Rehabilitation | Florence, AL | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Shoals Primary Care, Llc | 1557406246 | 43 |
News Archive
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.
› Verified 5 days ago
| Entity Name | Correct Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987441 PECOS PAC ID: 8628980992 Enrollment ID: O20040615000906 |
News Archive
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.
› Verified 5 days ago
| Entity Name | Shoals Primary Care, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326373861 PECOS PAC ID: 1557406246 Enrollment ID: O20100305000357 |
News Archive
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.
› Verified 5 days ago
| Entity Name | Lakeland Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851780951 PECOS PAC ID: 0446578298 Enrollment ID: O20150408000559 |
News Archive
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.
› Verified 5 days ago
| Entity Name | Northwest Alabama Emergency Medicine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639692767 PECOS PAC ID: 0749556611 Enrollment ID: O20171019003017 |
News Archive
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.
› Verified 5 days ago
| Entity Name | Keller Hospitalist Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235797200 PECOS PAC ID: 3870829161 Enrollment ID: O20190724002195 |
News Archive
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gilbert Reid Melson Iii, DO Po Box 2587, Muscle Shoals, AL 35662-2587 Ph: (256) 383-4473 | Dr Gilbert Reid Melson Iii, DO 2122 Helton Dr, Florence, AL 35630-1449 Ph: (256) 415-8680 |
News Archive
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.
› Verified 5 days ago
Dr. Edsel P Holden Ii, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3905 Peach St, Florence, AL 35630 Phone: 256-767-5864 Fax: 256-263-4512 | |
Khushdeep Singh Chahal, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 205 Marengo Street, Florence, AL 35630 Phone: 256-768-9509 Fax: 256-768-9715 | |
Dr. Heather Brody, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 180 Cox Creek Pkwy S Ste B, Florence, AL 35630 Phone: 256-760-0422 Fax: 256-284-6065 | |
John D Morris, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 205 Marengo Street, Florence, AL 35630 Phone: 256-768-9509 Fax: 256-768-9715 | |
Danny Wayne Mcfall, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 409 North Cedar Street, Florence, AL 35630 Phone: 256-766-3062 Fax: 256-767-1804 | |
Gabriel Hamilton Hester, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 205 Marengo St, Florence, AL 35630 Phone: 256-768-9509 Fax: 256-768-9715 | |
Dr. Rajesh Boorgu, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 422 E Dr Hicks Blvd, Florence, AL 35630 Phone: 256-766-1401 Fax: 256-766-1402 |